Bristol Myers Squibb Co's BMY VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM) met its primary endpoint at Week 16.
- The trial included symptomatic obstructive HCM patients who are eligible for septal reduction therapy (SRT).
- The safety of mavacamten was consistent with previous studies.
- "We look forward to sharing the results from VALOR-HCM at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in April," said Roland Chen, M.D., Senior Vice President, Cardiovascular Development at Bristol Myers Squibb.
- Related: Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay.
- The 100-subject trial includes three treatment periods: a 16-week placebo-controlled period, a 16-week active treatment period where all patients will receive mavacamten, and a 96-week long-term extension period where all patients will continue to receive mavacamten.
- Obstructive HCM is a chronic, progressive disease in which excessive heart muscle contraction and reduced ability of the left ventricle to fill can make it difficult for blood to circulate.
- Price Action: BMY shares are up 0.26% at $67.95 during the market session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.